Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States.
Eagle Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$50.64|
|52 Week High||US$36.48|
|52 Week Low||US$58.25|
|1 Month Change||-7.73%|
|3 Month Change||8.65%|
|1 Year Change||12.46%|
|3 Year Change||2.84%|
|5 Year Change||-25.64%|
|Change since IPO||294.70%|
Recent News & Updates
Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package
The results at Eagle Pharmaceuticals, Inc. ( NASDAQ:EGRX ) have been quite disappointing recently and CEO Scott Tarriff...
Eagle Pharmaceuticals: A Potential Reopening Play
Eagle Pharmaceuticals has felt the impact of COVID-19, and the earnings reports have reflected that. As a result, the share price has taken a beating over the past year. The company expects to see its earnings improve over the remainder of 2021 as the country begins to reopen and patients resume their chemo treatments. In addition to being a reopening play, I expect EGRX to be a great growth story in the coming years as they launch PEMFEXY and vasopressin in the coming quarters. I discuss my leading downside risk and reveal my plans for establishing a position in EGRX.
|EGRX||US Biotechs||US Market|
Return vs Industry: EGRX underperformed the US Biotechs industry which returned 17.8% over the past year.
Return vs Market: EGRX underperformed the US Market which returned 33.4% over the past year.
Stable Share Price: EGRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: EGRX's weekly volatility (5%) has been stable over the past year.
About the Company
Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.
Eagle Pharmaceuticals Fundamentals Summary
|EGRX fundamental statistics|
Is EGRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EGRX income statement (TTM)|
|Cost of Revenue||US$46.14m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||1.40|
|Net Profit Margin||9.68%|
How did EGRX perform over the long term?See historical performance and comparison
Is Eagle Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: EGRX ($50.64) is trading above our estimate of fair value ($30.2)
Significantly Below Fair Value: EGRX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: EGRX is poor value based on its PE Ratio (36.2x) compared to the US Biotechs industry average (24x).
PE vs Market: EGRX is poor value based on its PE Ratio (36.2x) compared to the US market (18.1x).
Price to Earnings Growth Ratio
PEG Ratio: EGRX is good value based on its PEG Ratio (0.3x)
Price to Book Ratio
PB vs Industry: EGRX is overvalued based on its PB Ratio (3.4x) compared to the US Biotechs industry average (2.9x).
How is Eagle Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EGRX's forecast earnings growth (108.4% per year) is above the savings rate (2%).
Earnings vs Market: EGRX's earnings (108.4% per year) are forecast to grow faster than the US market (14.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EGRX's revenue (10.5% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: EGRX's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EGRX's Return on Equity is forecast to be high in 3 years time
How has Eagle Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EGRX has high quality earnings.
Growing Profit Margin: EGRX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: EGRX's earnings have declined by 34.8% per year over the past 5 years.
Accelerating Growth: EGRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: EGRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: EGRX's Return on Equity (9.4%) is considered low.
How is Eagle Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: EGRX's short term assets ($175.5M) exceed its short term liabilities ($44.7M).
Long Term Liabilities: EGRX's short term assets ($175.5M) exceed its long term liabilities ($24.7M).
Debt to Equity History and Analysis
Debt Level: EGRX's debt to equity ratio (15.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if EGRX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: EGRX's debt is well covered by operating cash flow (151.4%).
Interest Coverage: EGRX's interest payments on its debt are well covered by EBIT (20.1x coverage).
What is Eagle Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EGRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EGRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EGRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EGRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EGRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Scott Tarriff (61 yo)
Mr. Scott L. Tarriff founded Eagle Pharmaceuticals Inc. in January 2007 and has been its Chief Executive Officer since January 2007, where he has helped build its market cap and has successfully marketed v...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD9.47M) is above average for companies of similar size in the US market ($USD2.26M).
Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.
Experienced Management: EGRX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: EGRX's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Eagle Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Eagle Pharmaceuticals, Inc.
- Ticker: EGRX
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$660.094m
- Shares outstanding: 13.10m
- Website: https://www.eagleus.com
Number of Employees
- Eagle Pharmaceuticals, Inc.
- 50 Tice Boulevard
- Suite 315
- Woodcliff Lake
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/27 22:09|
|End of Day Share Price||2021/10/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.